Mesoblast Limited EBIT

Mesoblast Limited (MEOBF) currently reports a EBIT of $-51M as of June 2026. That compares with $-62M in the prior-year period — up 17.9% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Mesoblast Limited's EBIT history and peer comparisons.

Mesoblast Limited's EBIT increased from $-62M to $-51M — a 17.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mesoblast Limited's EBIT of $-51M is lower than the Healthcare sector average of $22B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Mesoblast Limited reported $-51M in EBIT as of June 2026. That compares with $-62M in the prior-year period — up 17.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-51M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Mesoblast Limited, and consider following MEOBF for alerts when major investors trade the stock.